Lista de obras -

A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry.

artículo científico publicado en 2013

Clinical pharmacokinetics of tyrosine kinase inhibitors

artículo científico publicado en 2009

Dried blood spot analysis for therapeutic drug monitoring of pazopanib

artículo científico publicado en 2015

Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC.

artículo científico publicado en 2008

Effect of gastrointestinal resection on sunitinib exposure in patients with GIST.

artículo científico publicado en 2014

Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan

artículo científico publicado en 2005

Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial

scientific article published on 01 February 2017

Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study

scientific article published on 15 November 2019

Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib

artículo científico publicado en 2010

Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose

scientific article published on 21 January 2020

Individualized dosing of tyrosine kinase inhibitors: are we there yet?

artículo científico publicado en 2014

Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib

artículo científico publicado en 2007

Is rectal administration an alternative route for imatinib?

scientific article published on 08 February 2007

Marginal increase of sunitinib exposure by grapefruit juice

artículo científico publicado en 2010

Mitotane has a strong and a durable inducing effect on CYP3A4 activity.

artículo científico publicado en 2011

Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost-effectiveness study

artículo científico publicado en 2019

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity

artículo científico publicado en 2009

Reply to 'Hyperthermic intraperitoneal chemotherapy with oxaliplatin-Still not standard of care for patients with colorectal peritoneal metastases' by Julianov and Saroglu

artículo científico publicado en 2019

The effect of gastrectomy on regorafenib exposure and progression-free survival in patients with advanced gastrointestinal stromal tumours

artículo científico publicado en 2019

The relationship between sunitinib exposure and both efficacy and toxicity in real-world patients with renal cell carcinoma (RCC) and gastrointestinal stromal tumour (GIST)

scientific article published on 01 May 2020

Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study

artículo científico publicado en 2015

Lista de obras de

A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry.

Clinical pharmacokinetics of tyrosine kinase inhibitors

Dried blood spot analysis for therapeutic drug monitoring of pazopanib

Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC.

Effect of gastrointestinal resection on sunitinib exposure in patients with GIST.

Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan

Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial

Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study

Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib

Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose

Individualized dosing of tyrosine kinase inhibitors: are we there yet?

Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib

Is rectal administration an alternative route for imatinib?

Marginal increase of sunitinib exposure by grapefruit juice

Mitotane has a strong and a durable inducing effect on CYP3A4 activity.

Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost-effectiveness study

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity

Reply to 'Hyperthermic intraperitoneal chemotherapy with oxaliplatin-Still not standard of care for patients with colorectal peritoneal metastases' by Julianov and Saroglu

The effect of gastrectomy on regorafenib exposure and progression-free survival in patients with advanced gastrointestinal stromal tumours

The relationship between sunitinib exposure and both efficacy and toxicity in real-world patients with renal cell carcinoma (RCC) and gastrointestinal stromal tumour (GIST)

Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study